Market Overview

Genzyme's Once-Daily, Oral AUBAGIO Approved in Australia

Share:
Related SNY
Benzinga's Top Initiations
The 5 Top-Selling Drugs In The World
Biotech: What's Next For M&A? (Seeking Alpha)

Genzyme, a Sanofi company, (NYSE: SNY) announced today that the Australian Therapeutic Goods Administration (TGA) has approved AUBAGIO^® (teriflunomide) 14 mg as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS). The TGA approval will enable health professionals to prescribe AUBAGIO 14 mg in Australia, which is now the second country to gain marketing authorization for the treatment, following FDA approval in September.

Posted-In: News

 

Related Articles (SNY)

View Comments and Join the Discussion!